Anti-EBV Autologous TCR-T Cell therapy (Shanghai Jiao Tong University Affiliated First People'S Hospital)

N/A

Report date: 2025/09/24 20:02:07

Base Information

Drug NameAnti-EBV Autologous TCR-T Cell therapy (Shanghai Jiao Tong University Affiliated First People'S Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionAnti-Epstein-Barr virus
TargetsEpstein-Barr virus
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, Extranodal NK-T-CellLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Jiao Tong University Affiliated First People'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jiao Tong University Affiliated First People'S Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, Extranodal NK-T-CellLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A